Home Alzheimer’s Disease Study Results Appear to Support Larotrectinib Use in NTRK+ Lung Cancer

Study Results Appear to Support Larotrectinib Use in NTRK+ Lung Cancer

Frequent and durable antitumor responses as well as extended survival were noted with the use of larotrectinib (Vitrakvi) in patients with NTRK gene fusion–positive advanced lung cancer, and these benefits extended to patients with central nervous system (CNS) metastases.1

Results were collected from 14 patients enrolled in a phase 1 (n = 1) and a phase 2 (n = 13) clinical trial (NCT02122913 and NCT02576431, respectively) of larotrectinib who received 100 mg twice daily in continuous 28-day cycles and were presented during the 2020 World Conference on Lung Cancer Singapore. Thirteen patients had non–small cell lung cancer and 1 had small cell lung cancer. Half of the patients had CNS metastases at baseline. There were 11 patients (79%) with NTRK1 fusions and 3 (21%) had tumors with NTRK2 fusions.

Larotrectinib, a first-in-class, highly selective, and CNS-active TRK inhibitor,…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments